Abiopharma

🔍 KAPLAN ROBERT IRA (Director)

Company: Eagle Nuclear Energy Corp. (NUCL)

Report Date: 2026-05-06

Detailed Transactions and Holdings:

• Acquired 28,125 shares of Common Stock, par value $0.0001 per share (Direct)
  Date: 2026-05-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 28,125.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 9,375 shares of Stock Option (right to buy) at $9.15 per share (Derivative)
  Date: 2026-05-06 | Code: A | equity_swap_involved: 0 | shares_owned_after: 9,375.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: The securities reported in Column 4 of Table I are restricted stock units ("RSU"). Each RSU represents a contingent right to receive one share of common stock, par value $0.0001 per share, of Eagle Nuclear Energy Corp. (the "Issuer"), subject to the vesting schedule and other conditions set forth in the applicable RSU award and Issuer's 2025 Equity Incentive Plan. One-half of the RSUs vested upon grant and the remaining one-half will vest on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer.
• F2: Certain of the securities reported in Column 5 are RSUs, each representing a contingent right to receive one share of Common Stock, subject to the terms and conditions of the applicable RSU award agreement, including the vesting schedule set forth therein, and the Issuer's 2025 Equity Incentive Plan.
• F3: The stock options vest as follows: one-half vested upon grant and the remaining one-half will vest on the first anniversary of the grant date, subject to the reporting person's continued service with the Issuer and the terms and conditions of the applicable option award agreement and the Issuer's 2025 Equity Incentive Plan.